Rotavirus Vaccine Market Highlights

• Global rotavirus vaccine market revenue is poised to garner USD 26,012.1 million by 2032 with a CAGR of 10.3% from 2024 to 2032
• North America rotavirus vaccine market value occupied around USD 4,111.26 million in 2023
• Asia-Pacific rotavirus vaccine market growth will record a CAGR of more than 11% from 2024 to 2032
• Among type, the rotarix sub-segment generated noteworthy revenue in 2023
• Based on end-use, the hospital sub-segment generated significant rotavirus vaccine market share in 2023
• Growing support from international organizations, such as WHO and UNICEF is a popular rotavirus vaccine market trend that fuels the industry demand

Rotavirus is a contagious disease majorly affecting children and infants; watery diarrhea, vomiting, fever, and abdominal pain are some major symptoms witnessed by doctors.

Noticeable increase in number of patients suffering from various infections is resulting in government focus towards creating awareness among consumers related to available medications. Infection such as rotavirus has been impacting the lives of infants & children’s across the globe. Countries with poor resources are witnessing high death ratio. The mortality due to rotavirus across the globe is 600,000 each year and 80% of these deaths occur in less developed and poor countries. Rotavirus gastroenteritis results in only 20 to 70 childhood deaths per year in the United States. Rapid technological advancements in healthcare sector, increasing number of clinical trials by major players for development of new vaccines and increasing government spending on increasing the awareness among consumers are major factors expected to drive the growth of global rotavirus vaccine market. Major players are investing high for the development of new vaccines. Their approach towards decline the child hospitalization rate and lower the cost spent of rotavirus hospitalization.

Global Rotavirus Vaccine Market Dynamics

Market Drivers

• Growing prevalence of rotavirus infection among children
• Rise in the number of people with weakened immune systems
• Increase in the elderly population
• Expanding government immunization programs worldwide

Market Restraints

• Uncertain demand from non-GAVI middle-income countries (MICs)
• Concerns about the vaccinations' potential side effects
• Limited healthcare infrastructure in low-income regions

Market Opportunities

• Increase in the overall population and live births
• Rising awareness campaigns promoting rotavirus vaccination
• Development of low-cost vaccines to improve accessibility in underserved regions

Rotavirus Vaccine Market Report Coverage

Rotavirus Vaccine Market Insights

Players are focused on enhancing the business through new product launches and acquisitions. Their approach towards securing long time contracts in order to enhance the revenue share are factors expected to impact the growth of rotavirus vaccine market value. In 2021, GSK a global drugs manufacturer signed a contract with UNICEF to supply its rotavirus vaccine, Rotarix, through the Humanitarian Mechanism for civil society organizations serving the vaccination needs of refugee and other emergency situations. In 2021, Bharat Biotech, a global drug developer received award “BioSpectrum Product of the Year Award 2020” for its rotavirus vaccine, “ROTAVAC 5D”. The vaccine is safe and effective in the prevention of rotavirus diarrhea. This is expected to help company attract new customers and increase product sale.

Factors such as high cost associated to vaccine development and strict government regulations related to product approval are factors expected to hamper the growth of global rotavirus vaccine market size. The drug regulatory bodies are implementing stringent regulations for the approval of drugs. In 2010, The US Food and Drug Administration (FDA), in public meeting advised healthcare practitioners to temporarily stop using of GlaxoSmithKline's (GSK's) Rotarix rotavirus vaccine. The vaccine has presence of porcine circovirus 1 (PCV1) in the product which is harmful.

In addition, high price of vaccine for the low economic growth countries is expected to challenge the rotavirus vaccine market growth. However, increasing investment for drug development from major players and development of low cost vaccines are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing partnership and contract between private and public enterprises is expected to support the revenue transaction of target market.

Rotavirus Vaccine Market Segmentation

The worldwide market for rotavirus vaccine is split based on type, end-use, and geography.

Rotavirus Vaccine Types

• Lanzhou Lamb
• Rotarix
• Rotavac
• Rotavin-M1
• Others

According to rotavirus vaccine industry analysis, rotarix is anticipated to become a substantial market sector. Rotarix, a vaccine manufactured by GlaxoSmithKline, is widely used and provides adequate protection against rotavirus infections, particularly in young children. Its appeal arises mostly from its established efficacy, safety profile, and widespread availability in a number of countries.Rotarix is administered in a two-dose regimen, making it simpler and more convenient than vaccines that require multiple doses, increasing its popularity in both developed and developing countries. Furthermore, the World Health Organization (WHO) recommends Rotarix for use in global immunization programs, particularly in low-income countries, which will increase its uptake and solidify its position as a leading vaccine in the fight against rotavirus.

Rotavirus Vaccine End-Use

• Hospitals
• Clinics
• Academic & Research Lab

Hospitals own roughly 51% of the rotavirus vaccine market share. Hospitals play a crucial role in providing rotavirus vaccines, particularly in urban and semi-urban areas where healthcare is more readily available. Hospitals receive a large number of patients, particularly infants and young children, who are more susceptible to rotavirus infection. Furthermore, government-sponsored immunization programs and agreements with organizations such as the World Health Organization usually make use of hospital networks to efficiently provide vaccines. Hospitals also have the infrastructure and qualified staff to monitor post-vaccination outcomes, making them essential for safe and effective rotavirus immunization.

Rotavirus Vaccine Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Rotavirus Vaccine Market Regional Analysis

Rotavirus vaccine demand in North America is being pushed by factors such as high birth rates, a proactive approach to immunization, and an increased emphasis on preventative healthcare. The United States, as a major contributor, benefits from the inclusion of rotavirus vaccinations in normal pediatric immunization schedules, which ensures universal vaccination coverage. Furthermore, commercial and public healthcare professionals in the region are making a concerted effort to reduce rotavirus-related hospitalizations, which is increasing vaccination use.

Canada also plays an important role in the regional economy, because to its well-organized healthcare system, which promotes early childhood vaccines. Several provinces have included rotavirus vaccinations in their immunization schedules, demonstrating significant government backing. This proactive approach, combined with public education activities, is expected to promote the consistent expansion of North America's rotavirus vaccination.

Rotavirus Vaccine Market Players

Some of the top rotavirus vaccine companies offered in our report includes BIOVIRx Inc, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Bharat Biotech, Biological E, Bio Farma, Novartis AG, GlaxoSmithKline plc., Sanofi, Lanzhou Institute of Biologicals Products Co., Ltd, Berghofer Medical Research Institute, and Pfizer, Inc.